Pharmaceuticals, Biotechnology and Life Sciences
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operationsFOSTER CITY, Calif., Oct. 13, 2025…
CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical…
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) — Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and…
Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the official launch…
AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO…
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer…
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025,…
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a…
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in…